MX2020007771A - Metodos para la supervision de la deteccion y el tratamiento de cancer de colon. - Google Patents

Metodos para la supervision de la deteccion y el tratamiento de cancer de colon.

Info

Publication number
MX2020007771A
MX2020007771A MX2020007771A MX2020007771A MX2020007771A MX 2020007771 A MX2020007771 A MX 2020007771A MX 2020007771 A MX2020007771 A MX 2020007771A MX 2020007771 A MX2020007771 A MX 2020007771A MX 2020007771 A MX2020007771 A MX 2020007771A
Authority
MX
Mexico
Prior art keywords
methods
colon cancer
cancer detection
treatment monitoring
determining
Prior art date
Application number
MX2020007771A
Other languages
English (en)
Spanish (es)
Inventor
Mark Kidd
Irvin Mark Modlin
Ignat Drozdov
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of MX2020007771A publication Critical patent/MX2020007771A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
MX2020007771A 2018-01-22 2019-01-22 Metodos para la supervision de la deteccion y el tratamiento de cancer de colon. MX2020007771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862620015P 2018-01-22 2018-01-22
PCT/US2019/014490 WO2019144099A1 (en) 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring

Publications (1)

Publication Number Publication Date
MX2020007771A true MX2020007771A (es) 2020-09-03

Family

ID=65279827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007771A MX2020007771A (es) 2018-01-22 2019-01-22 Metodos para la supervision de la deteccion y el tratamiento de cancer de colon.

Country Status (14)

Country Link
US (3) US11414707B2 (cg-RX-API-DMAC7.html)
EP (1) EP3743534B1 (cg-RX-API-DMAC7.html)
JP (1) JP7297770B2 (cg-RX-API-DMAC7.html)
CN (1) CN112004945B (cg-RX-API-DMAC7.html)
AU (1) AU2019209436B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014737A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088754A1 (cg-RX-API-DMAC7.html)
DK (1) DK3743534T3 (cg-RX-API-DMAC7.html)
ES (1) ES2917629T3 (cg-RX-API-DMAC7.html)
IL (1) IL276089B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020007771A (cg-RX-API-DMAC7.html)
PL (1) PL3743534T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202006974WA (cg-RX-API-DMAC7.html)
WO (1) WO2019144099A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3743534T3 (da) 2018-01-22 2022-06-20 Liquid Biopsy Res Llc Fremgangsmåde til påvisning af coloncancer og behandlingsovervågning
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
US11809379B2 (en) * 2019-11-19 2023-11-07 International Business Machines Corporation Storage tiering for deduplicated storage environments
CN111157745A (zh) * 2020-01-17 2020-05-15 上海交通大学 人snrpa蛋白在肺癌复发或转移监测中的用途
CN115475247B (zh) * 2021-06-16 2024-02-20 厦门大学 β2-微球蛋白或其抑制剂的制药用途
CN113921079B (zh) * 2021-12-06 2022-03-18 四川省肿瘤医院 基于免疫相关基因的msi预测模型构建方法
CN121137146B (zh) * 2025-07-28 2026-04-07 首钢医院有限公司 检测基因组合物的试剂在制备预测结直肠癌患者远端切缘长度的产品中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2169077A1 (en) * 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
EP2169078A1 (en) * 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer
KR101051435B1 (ko) * 2008-10-22 2011-07-22 한국생명공학연구원 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법
KR101073875B1 (ko) * 2008-11-28 2011-10-14 한국생명공학연구원 대장암 진단 마커 및 이를 이용한 대장암 진단방법
EP2425020A4 (en) 2009-05-01 2016-04-20 Genomic Health Inc GENE EXPRESSION PROFILE GORITHM AND TEST OF PROBABILITY OF REPRODUCTION OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY
EP2309002A1 (en) * 2009-09-29 2011-04-13 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of colorectal cancer aggressiveness
EP2553118B1 (en) * 2010-03-31 2014-10-15 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
CN103403187A (zh) * 2011-01-18 2013-11-20 艾沃锐斯特基因有限公司 结肠直肠癌复发的预后特征
SG192108A1 (en) * 2011-01-25 2013-08-30 Almac Diagnostics Ltd Colon cancer gene expression signatures and methods of use
WO2014041185A2 (en) * 2012-09-17 2014-03-20 Ait Austrian Institute Of Technology Gmbh Colon cancer diagnostic method and means
MX2015006757A (es) * 2012-11-30 2015-11-30 Applied Proteomics Inc Método para la evaluación de la presencia de o riesgo de tumores de colon.
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
DK3743534T3 (da) 2018-01-22 2022-06-20 Liquid Biopsy Res Llc Fremgangsmåde til påvisning af coloncancer og behandlingsovervågning

Also Published As

Publication number Publication date
AU2019209436B2 (en) 2025-06-05
IL276089B1 (en) 2024-03-01
US20190226030A1 (en) 2019-07-25
CN112004945A (zh) 2020-11-27
WO2019144099A1 (en) 2019-07-25
CN112004945B (zh) 2025-02-14
US20250243553A1 (en) 2025-07-31
JP7297770B2 (ja) 2023-06-26
US11414707B2 (en) 2022-08-16
DK3743534T3 (da) 2022-06-20
ES2917629T3 (es) 2022-07-11
SG11202006974WA (en) 2020-08-28
US20230220482A1 (en) 2023-07-13
AU2019209436A1 (en) 2020-08-06
IL276089A (en) 2020-08-31
EP3743534B1 (en) 2022-03-23
EP3743534A1 (en) 2020-12-02
IL276089B2 (en) 2024-07-01
US12305240B2 (en) 2025-05-20
BR112020014737A2 (pt) 2020-12-08
PL3743534T3 (pl) 2022-09-05
JP2021511057A (ja) 2021-05-06
CA3088754A1 (en) 2019-07-25
KR20200113237A (ko) 2020-10-06

Similar Documents

Publication Publication Date Title
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
CY1125020T1 (el) Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων
WO2015109263A3 (en) Biomarkers for detecting and monitoring colon cancer
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
EP4553840A3 (en) Systems and methods for analyzing nucleic acid
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
CY1125201T1 (el) Προφαρμακα του αναστολεα ειδικου προστατικου αντιγονου μεμβρανης (psma)
WO2018136919A3 (en) Methods relating to lung cancer
MX2016004283A (es) Biomarcadores para la actividad, e intesidad y arrebato de la enfermedad lupus eritematoso sistemico.
MX2016007066A (es) Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.
HK1220253A1 (zh) 诊断前列腺癌症的方法
EA201691314A1 (ru) Терапевтические способы и композиции
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
IL276089A (en) Methods for colon cancer detection and treatment monitoring
WO2014042828A3 (en) Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
WO2017057778A3 (en) Use of laminin 2 for diagnosing hepatocellular carcinoma and pancreatic cancer
SG10201806729VA (en) Novel assay to detect human periostin
WO2012019132A3 (en) Anaplastic lymphoma kinase in kidney cancer
WO2016133449A9 (en) Detection and treatment of malignant tumours in the cns
NZ729773A (en) Biomarkers for disease progression in melanoma
EP4428251A3 (en) Methods of detecting prostate cancer
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy
MX2020000785A (es) Metodos para la deteccion de discrasia de celulas plasmaticas.
EP3640643A3 (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
MX369175B (es) Métodos para detectar mutantes de akt resistentes a fármacos.